Currently available GLP-1 receptor agonists in the United States include exenatide (Byetta, Bydureon BCise), liraglutide (Victoza, Saxenda), dulaglutide (Trulicity), semaglutide (Ozempic, Wegovy, Rybelsus), and tirzepatide (Mounjaro, Zepbound), though tirzepatide is technically a dual GIP/GLP-1 receptor agonist
Take in divided doses of 500mg or less for optimal absorption
Dont let your weight hold you back any longer
Even in an approved product, oral semaglutide exhibits very low bioavailability, typically below 1%, which necessitates higher dosing and contributes to cost, variability, and formulation complexity
Fluid needs vary by individual
It reveals predispositions in GIPR, FTO, and MC4R pathways to support personalized treatment conversations with your provider